These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19483750)

  • 1. Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular disease.
    Manca-di-Villahermosa S; Taccone-Gallucci M; Maccarrone M
    Kidney Int; 2009 Jun; 75(12):1354-1355. PubMed ID: 19483750
    [No Abstract]   [Full Text] [Related]  

  • 2. Should statins be prescribed for primary prevention of cardiovascular disease in patients with chronic kidney disease?
    Connor A; Tomson C
    BMJ; 2009 Aug; 339():b2949. PubMed ID: 19696089
    [No Abstract]   [Full Text] [Related]  

  • 3. [Statins in chronic renal disease].
    Ferreira SR; Rocha AM; Saraiva JF
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():45-9. PubMed ID: 16400399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG CoA reductase inhibitors (statins) for dialysis patients.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Nigwekar SU; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD004289. PubMed ID: 24022428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephroprotective and clinical potential of statins in dialyzed patients.
    Rysz J; Aronow WS; Stolarek RS; Hannam S; Mikhailidis DP; Banach M
    Expert Opin Ther Targets; 2009 May; 13(5):541-50. PubMed ID: 19368496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for end-stage kidney disease treated with dialysis.
    Webster A; Palmer S; Ruospo M; Strippoli GF
    Nephrology (Carlton); 2015 Apr; 20(4):302-3. PubMed ID: 25810229
    [No Abstract]   [Full Text] [Related]  

  • 7. Statins do not improve cardiovascular outcomes for dialysis patients.
    Olyaei A
    Evid Based Med; 2014 Jun; 19(3):89. PubMed ID: 24336608
    [No Abstract]   [Full Text] [Related]  

  • 8. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin in patients undergoing hemodialysis.
    de Oliveira JM
    N Engl J Med; 2009 Jul; 361(1):93-4; author reply 94-5. PubMed ID: 19579278
    [No Abstract]   [Full Text] [Related]  

  • 10. Statins in the prevention of cardiovascular events in patients with renal failure.
    Buemi M; Floccari F; Nostro L; Campo S; Caccamo C; Sturiale A; Aloisi C; Giacobbe MS; Frisina N
    Cardiovasc Hematol Disord Drug Targets; 2007 Mar; 7(1):7-13. PubMed ID: 17346123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin in patients undergoing hemodialysis.
    Kassimatis TI; Konstantinopoulos PA
    N Engl J Med; 2009 Jul; 361(1):93; author reply 94-5. PubMed ID: 19579277
    [No Abstract]   [Full Text] [Related]  

  • 12. Statin use prolongs patient survival after renal transplantation.
    Ritz E; Wanner C
    J Am Soc Nephrol; 2008 Nov; 19(11):2037-40. PubMed ID: 18842988
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical implications of statin therapy in patients undergoing hemodialysis.
    Kim JJ; Langworthy DR; Hennessey EK
    Am J Health Syst Pharm; 2014 May; 71(9):703-10. PubMed ID: 24733132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.
    Seliger SL; Weiss NS; Gillen DL; Kestenbaum B; Ball A; Sherrard DJ; Stehman-Breen CO
    Kidney Int; 2002 Jan; 61(1):297-304. PubMed ID: 11786112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin in patients undergoing hemodialysis.
    Ganguli A
    N Engl J Med; 2009 Jul; 361(1):93; author reply 94-5. PubMed ID: 19571292
    [No Abstract]   [Full Text] [Related]  

  • 16. Charting new territory by simulated modeling of a clinical trial.
    Tuttle KR
    Clin J Am Soc Nephrol; 2010 May; 5(5):750-2. PubMed ID: 20360306
    [No Abstract]   [Full Text] [Related]  

  • 17. Sunset for statins after AURORA?
    Strippoli GF; Craig JC
    N Engl J Med; 2009 Apr; 360(14):1455-7. PubMed ID: 19332454
    [No Abstract]   [Full Text] [Related]  

  • 18. Statin effects in CKD: is there a "point of no return"?
    Wanner C
    Am J Kidney Dis; 2009 May; 53(5):723-5. PubMed ID: 19393469
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular death in dialysis patients: lessons we can learn from AURORA.
    Sniderman AD; Solhpour A; Alam A; Williams K; Sloand JA
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):335-40. PubMed ID: 20056762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of chronic inflammation in cardiovascular mortality of uremic patients.
    Panichi V; Taccola D; Migliori M; Consani C; Giovannini L; Tetta C
    Int J Artif Organs; 2003 Jan; 26(1):12-8. PubMed ID: 12602464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.